NETSTREIT secures $550 million in financing commitments

NETSTREIT (NTST) secured $550M in financing, extending debt maturities and repaying a $200M term loan due in 2028. The financing includes a $100M increase to its existing senior credit facility. According to the company, this strengthens its financial position.

NETSTREIT Corp. (NTST) secured $550M in additional term loans, repaid a $200M 2028 term loan, and extended maturities until early 2029. According to the company, this move is part of its balance sheet management strategy.

NETSTREIT expanded its financing by adding $150 million to existing term loans and securing a new $400 million delayed draw facility maturing in 2033. The company also amended credit agreements with Wells Fargo, PNC, and Truist to reduce costs and align terms. These moves aim to lower borrowing costs, streamline documentation, and enhance liquidity.

NETSTREIT Corp. (NTST) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 netstreitearningsrelease.htm EX-99.1 Document NETSTREIT REPORTS SECOND QUARTER 2026 FINANCIAL AND OPERATING RESULTS – Net Income of $0.06 and Adjusted Funds from Operations ("AFFO") of $0.35 Per Diluted Share – – Completed Strong Gross Investment Activity of $298.9 Mill

Pyxis Oncology (NASDAQ:PYXS) raised $110M from a public offering, selling 36M shares at $2.90 each and warrants. Additional proceeds of $172.6M could be raised if milestone-linked warrants are exercised. Proceeds will fund clinical trials and general corporate purposes, with data updates expected in 2026-2027.

Pyxis Oncology (PYXS) closed a public offering, raising $110M upfront. The deal includes milestone-linked warrants that could add $172.6M if exercised, totaling $282.6M. Proceeds will fund clinical trials, including MICVO for head and neck cancer, and general corporate purposes. The offering involved new and existing institutional investors.